Meetings

The Molecular Tumor Board (MTB) meets:

  • 12 p.m.
  • Every first and third Tuesday
  • Room CC 457, Ben F. Roach Building

Off-site participants can call in via UK Telehealth. Email the MTB manager to be added to the call in list.

Some MTB meetings will include a 15-minute informational update on Precision Medicine. See Schedule for Topics and Speakers.

To schedule a case presentation, review the details in the Case Submission section. All cases must be submitted to MTB seven days prior to meeting date.

Journal Club

The MTB Journal Club meets to evaluate current research regarding oncology-based precision medicine.

  • 1 p.m.
  • Every first Tuesday
  • Room CC 457, Ben F. Roach Building

    MTB Meeting Schedule

    Case Submission Date   Meeting Date 15 Minute Update Topic  Speaker
    01/31/17 02/07/17    
    02/14/17 02/21/17    
    02/28/17 03/07/17    
    03/14/17 03/21/17    
    03/28/17 04/04/17    
    04/11/17 04/18/17    
    04/25/17 05/02/17    
    05/09/17 05/16/17    
    05/30/17 06/06/17    
    06/13/17 06/20/17    
    07/11/17 07/18/17    
    07/25/17 08/01/17    
    08/08/17 08/15/17    
    08/29/17 09/05/17    
    09/12/17 09/19/17    
    09/26/17 10/03/17    
    10/10/17 10/17/17    
    10/31/17 11/07/17    
    11/14/17 11/21/17    
    11/28/17 12/05/17    
    12/12/17 12/19/17    


    Continuing Medical Education (CME)

    If clinicians or pharmacists want to obtain CE Credit for this meeting, they must attend the meeting in person or via teleconference, then enter the provided access code on the  CE Central website. Any questions or concerns regarding CE Credit can be directed to the MTB Manager at  mtb@uky.edu

    Policy on Disclosure

    It is the policy of the Markey Cancer Center that the faculty, authors, planners and other persons who may influence the content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow CME staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation.

    Page last updated: 8/21/2017 3:43:24 PM